NCT05406713View on ClinicalTrials.gov

Pembrolizumab in Muscle-invasive Bladder Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Muscle Invasive Bladder CarcinomaLocalized CancerUrothelial Carcinoma
Interventions
DRUG

Pembrolizumab

400 mg intravenously

Trial Locations (4)

10029

Icahn School of Medicine at Mount Sinai, New York

46202

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

87102

University of New Mexico Comprehensive Cancer Center, Albuquerque

91010

City of Hope, Duarte

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Matthew Galsky

OTHER

NCT05406713 - Pembrolizumab in Muscle-invasive Bladder Cancer | Biotech Hunter | Biotech Hunter